210 related articles for article (PubMed ID: 15730171)
1. Dose effects of progesterone in add-back therapy during GnRHa treatment.
Cheung TH; Lo KW; Yim SF; Lam C; Lau E; Haines C
J Reprod Med; 2005 Jan; 50(1):35-40. PubMed ID: 15730171
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis.
Akira S; Mine K; Kuwabara Y; Takeshita T
Med Sci Monit; 2009 Jan; 15(1):CR1-4. PubMed ID: 19114964
[TBL] [Abstract][Full Text] [Related]
3. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Chwalisz K; Surrey E; Stanczyk FZ
Reprod Sci; 2012 Jun; 19(6):563-71. PubMed ID: 22457429
[TBL] [Abstract][Full Text] [Related]
4. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
5. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey ES
Curr Opin Obstet Gynecol; 2010 Aug; 22(4):283-8. PubMed ID: 20498596
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy and safety of domestic luteinizing hormone-releasing hormone analogue and low-dose norethindrone "add-back" therapy in the treatment of endometriosis].
Zhang S; Ye G; Chen H
Zhonghua Fu Chan Ke Za Zhi; 2000 Aug; 35(8):482-5. PubMed ID: 11776204
[TBL] [Abstract][Full Text] [Related]
8. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
Hornstein MD; Surrey ES; Weisberg GW; Casino LA
Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
[TBL] [Abstract][Full Text] [Related]
9. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
[TBL] [Abstract][Full Text] [Related]
10. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
11. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial.
Fernandez H; Lucas C; Hédon B; Meyer JL; Mayenga JM; Roux C
Hum Reprod; 2004 Jun; 19(6):1465-71. PubMed ID: 15105403
[TBL] [Abstract][Full Text] [Related]
12. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
Surrey ES; Judd HL
J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder.
Segebladh B; Borgström A; Nyberg S; Bixo M; Sundström-Poromaa I
Am J Obstet Gynecol; 2009 Aug; 201(2):139.e1-8. PubMed ID: 19398092
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
15. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.
Surrey ES; Hornstein MD
Obstet Gynecol; 2002 May; 99(5 Pt 1):709-19. PubMed ID: 11978277
[TBL] [Abstract][Full Text] [Related]
16. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.
Surrey ES; Voigt B; Fournet N; Judd HL
Fertil Steril; 1995 Apr; 63(4):747-55. PubMed ID: 7890057
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
18. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
Brynhildsen J; Hammar M
Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
[TBL] [Abstract][Full Text] [Related]
19. Current approaches to optimizing the treatment of endometriosis in adolescents.
Laufer MR
Gynecol Obstet Invest; 2008; 66 Suppl 1():19-27. PubMed ID: 18936548
[TBL] [Abstract][Full Text] [Related]
20. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain.
Bedaiwy MA; Casper RF
Fertil Steril; 2006 Jul; 86(1):220-2. PubMed ID: 16716325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
